Inflammatory myopathies

Disease characteristics and medications use in idiopathic inflammatory myopathy: a multi-centre prospective observational study of decentralized remote vs. traditional clinic enrolment

Rheumatology (Oxford)Published Prospective observational cohort study

Authors' conclusion

Tele-research recruitment yielded a patient cohort resembling traditionally recruited patients demographically and clinically, indicating its effectiveness for robust and diverse patient recruitment in clinical studies.

Study context

Population
US patients with idiopathic inflammatory myopathies (IIM)
Participants
120 patients
Exposure
Tele-research cohort vs centre-based cohort
  • Tele-research cohort (TRC)n = 82
  • Centre-based cohort (CBC)n = 38reference
Outcome
Disease characteristics (baseline demographic and clinical variables, organ involvement, diagnostic tests results and medication use) compared between remote and clinic-recruited patients
Follow-up
Baseline
Methodological detailsmulticentre, decentralized remote vs traditional clinic enrolment
  • Multicentre
  • Decentralized remote vs traditional clinic enrolment

Main finding

As reported in the abstract

Disease characteristics, TRC vs CBC
Comparable IIM subtype prevalence among cohorts
P = 0.85
TRC patients received biologics more frequently
P < 0.001
TRC patients received csDMARDs more frequently
P = 0.013

Observational data: associations, not effects.

Further findings

Overall cohort characteristics · baseline

Average age
55 ± 13.4
Females
75%
Caucasians
81%
DM
41%
PM
27%
Anti-synthetase syndrome
23%
Necrotizing myositis
9%

Original publication

Disease characteristics and medications use in idiopathic inflammatory myopathy: a multi-centre prospective observational study of decentralized remote vs. traditional clinic enrolment. Rheumatology (Oxford). Published 29 August 2024. doi:10.1093/rheumatology/keae467

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.